History

How the Molina Story Bent

For most of the last decade Molina Healthcare was a model of management credibility — a board-installed CEO who said exactly what he would do and then did it, year after year. That story broke in 2025. Initial 2025 EPS guidance of "at least \$24.50" was reaffirmed in April, lowered to a "no less than \$19" floor in July, cut again to "approximately \$14" in October, and the year finished at GAAP \$8.92 — a 64% miss against the original number, across three separate guidance cuts in a single year. The current narrative — that 2025 was an industry-wide rate/trend dislocation that the Medicaid business will outgrow — is internally consistent and being delivered with the same level of detail and conservatism that built the franchise. But credibility, once spent, returns slowly.

A Single Pivot Defines the Modern Company

Molina runs on a single, knife-edge division between two eras. Everything before November 2017 is the founding-family era; everything since is Joseph Zubretsky.

1980–2017 — the founder era. Molina was founded in 1980 by Dr. C. David Molina as a network of Medicaid clinics in California, ran as a family business under his son Dr. J. Mario Molina from 1996, and went public in 2003 at \$644 million of revenue and 511,000 members [1]. It expanded steadily for fourteen years until 2017 detonated: revenue still grew to \$19.9 billion but the company posted a net loss of -\$512 million on operating losses of -\$555 million, driven by Marketplace mispricing and an over-spent G&A base. The Molina brothers were terminated in May 2017 and the board recruited Joseph Zubretsky, then CEO of The Hanover Group and previously CFO of Aetna, who joined as President and CEO in November 2017 [2].

Inherited quality: no. The business Zubretsky walked into was a damaged franchise — a great Medicaid distribution platform attached to a control environment that had just lost \$500 million. The lean Medicaid book, the rebuild of margins, and the M&A roll-up that followed are this team's work, not an inheritance. Every other tab in this report should read 2018 onward as the Zubretsky era and the years before as a different company.

The chart tells the whole arc on one frame: the 2017 trough (-\$512M), the 2018 reset, the 2019–2020 stabilization, the 2021–2024 M&A roll-up, and the 2025 earnings collapse that is the entire reason this tab matters.

The 2018–2024 Era: A Playbook That Worked

For seven straight years the formula was the same and the formula worked. Zubretsky inherited a stable Medicaid distribution platform, dropped the unprofitable Marketplace exposure, used the cash flow to fund a string of "fixer-upper" Medicaid book acquisitions, and built an investor narrative around two phrases used quarter after quarter: "embedded earnings power" (the run-rate accretion from acquired books and new RFP wins not yet in current EPS) and a commitment that management would "not just declare goals, but show you the playbook" with transparency and specificity [3].

By Q2 2021 the formula was already showing through the COVID noise: \$6.6 billion of premium revenue, a 6.9% G&A ratio, after-tax margin of 2.9% in line with internal expectations, and guidance for 2021 raised to "no less than \$13.25" of adjusted EPS, with management explicitly framing the playbook as one of acquiring "stable membership and revenue streams, particularly focused on underperforming properties" [4] [5]. They closed Affinity in Q4 2021, Cigna's MA book in 2022, My Choice Wisconsin in 2023, Bright HealthCare's California MA book in early 2024, and ConnectiCare in early 2024, and on Form RFP they won Iowa, Nebraska, Texas, Georgia, Ohio, Michigan, Massachusetts, and Idaho through 2023–2024 [6].

The financial proof that the playbook compounded:

Revenue grew from \$16.8B in 2019 to \$40.7B in 2024 — 19% CAGR over five years, mostly through M&A. EPS went from \$11.47 to \$20.42 over the same period. Operating margin held in a tight 3.7%–6.2% band — exactly the "mid-teens EPS, 3–4% after-tax margin" frame management committed to at the 2021 Investor Day [7]. The 2024 result of \$22.65 adjusted EPS on \$38.6 billion of premium was actually the first modest miss of the era — full-year guidance had been "at least \$23.50" — and management called it out cleanly: "our full year results falling below our guidance" [8].

This was the credibility that 2025 was about to spend.

The 2025 Break: Three Cuts in One Year

The trajectory of the 2025 guidance is the most consequential single fact in Molina's modern history. The Q4 2024 call introduced 2025 EPS guidance "at least \$24.50 per share, which is approximately 8% year-over-year growth," explicitly built on a 4.5% Medicaid trend assumption and a 79% Marketplace MCR [9]. The Q1 2025 call on April 24 reaffirmed both the \$42 billion premium target and the \$24.50 EPS floor [10], even acknowledging higher cost trend, claiming the rate cycle had captured it.

Twelve weeks later, on July 7, management preannounced a cut. On July 24 the Q2 call set a new "no less than \$19" floor — \$5.50 below original guidance and \$3 below the July 7 midpoint — and characterized the medical-cost environment as "unprecedented" [11]. Three months after that, on October 23, the floor was abandoned and guidance dropped to "approximately \$14," a "\$10.50 revision" from the initial number, with management explicitly noting that "Marketplace was initially projected to produce over \$3 of earnings per share, but is now expected to produce a loss of \$2 per share, a swing of over \$5" — out of a business that is 10% of revenue [12]. The year ultimately closed at \$8.92 GAAP / lower-than-\$14 adjusted, against an initial \$24.50.

Where the \$15+ of EPS actually went

The Q3 2025 call disaggregated the \$10.50 cut through October: Marketplace (10% of revenue) accounted for half — a "swing of over \$5"; Medicaid (75% of revenue) accounted for roughly one-third; Medicare absorbed the rest [12]. The FY2025 10-K is candid about the mechanics: the consolidated MCR ran 91.7% versus 89.1% in 2024 — 260 basis points of medical-cost-trend-driven deterioration — and the Medicaid MCR alone rose 150 basis points to 91.8%, with rate increases "lagged the increase in medical cost trend, resulting in a rate and trend imbalance that we believe to be temporary" [13] [14].

The pattern matters more than the magnitude: every part of the business broke at once. Medicaid trend (~7%) outran rate (~5.5%); Medicare rates didn't keep pace with high-acuity-duals utilization; Marketplace risk adjustment, which had carried the segment for two consecutive years of mid-70s MCRs, suddenly stopped offsetting a higher market-wide acuity pool — the Wakely industry data confirmed Molina's miss was directional, not idiosyncratic [15].

The Buyback Question

The story that should be most uncomfortable for the credibility verdict is the timing of capital return.

In Q1 2025, with EPS guidance still at \$24.50, Molina spent \$500 million on a 1.7 million-share buyback. In Q3 2025, the same quarter the floor was breaking and the cut to \$14 was being communicated, management repurchased an additional 2.8 million shares "at a cost of \$500 million" — explicitly stating "we see real value in our shares at current market prices, which we believe at this low point in the rate cycle underappreciate the longer-term margin targets of our business" [16].

The cumulative effect: parent-company cash dropped from \$445 million at end-2024 to \$108 million at end-Q3 2025 [16], debt-to-EBITDA temporarily ran up to 2.5×, operating cash flow swung from +\$644 million in 2024 to negative \$535 million in 2025 [17], and by Q1 2026 leverage had reached 6.1× trailing-twelve-month EBITDA — though Mark Keim flagged this as "temporarily" elevated by transient timing items [18]. The buyback wasn't reckless given the discount management saw, but it was the wrong half of the year to execute it; the same \$500 million returned post-Q4 would have sat against a much lower share price.

A self-styled "playbook" CEO who reaffirms \$24.50 EPS in April, then prints \$14 in October, then buys \$1B of his own stock at the high end of the year, has more explaining to do than the standard "industry-wide medical-cost dislocation" framing offers.

Narrative Drift: What Management Stopped Saying

The drift is more telling than the headline cut. Three phrases that were ubiquitous in 2021–2024 are quietly gone or repositioned in 2025:

The phrase "transparency and specificity… we will not just declare our goals but show you the playbook" [3] — which appeared in essentially every prepared remark from 2018 through 2024 — barely surfaces in 2025. The Q3 2025 substitute is "the magnitude and persistence of these medical cost increases are unprecedented" [15]: a defensible framing, but a different tone.

The "13% to 15% long-term EPS growth" target, reaffirmed as recently as the Q1 2025 call in April [19], has been replaced by a 2026 base of "at least \$5" — a number that is below 2018's \$11.85, lower than any year since the founder-era trough [20]. The math on a 13–15% CAGR off a \$5 base puts the company back at 2024's \$20+ EPS only by 2031.

The biggest structural drift is in the risk-factor section of the 10-K itself. In FY2021 the headline risk on the cover of the risk factors was COVID-19; through 2023 it was rate/trend uncertainty in Medicaid. In the FY2025 10-K, "Our Marketplace business has been volatile and unpredictable, and has been subject to annual programmatic changes that are difficult to price for actuarially" is now listed at the very top of Risk Factors — repositioned ahead of every Medicaid risk [21]. Management is telling readers what they had previously absorbed quietly: Marketplace was always volatile, they sized into it for growth, and it was the wrong call.

The Promises Track Record — Honest Scorecard

No Results

Four out of five years met or beat the original number — and the one modest miss in 2024 was acknowledged plainly on the very next call [8]. Then 2025 broke the pattern catastrophically. The intellectual honesty is intact — the Q3 call reconciled the \$10.50 cut segment-by-segment, the 10-K MD&A says explicitly that "the Medicaid MCR for 2025 is higher than we expected and is above our long-term target range" [14] — but a miss this large doesn't get explained away by industry framing alone.

The Current Chapter: A Conservative Reset

The Q1 2026 call on April 23 reaffirmed FY2026 guidance of "approximately \$42 billion of premium revenue and at least \$5 in adjusted earnings per share" — a 75% drop from 2024's \$20.42, lower than any post-2017 year [20]. The conservatism is the point: even with a Q1 2026 actual of \$2.35 implying a stronger setup, management chose not to raise guidance, noting Q1 trend "annualized would put us at better than 5% for the full year" while still holding the number until June Wakely data validates the Marketplace baseline.

Three concrete pricing actions distinguish 2026 from the 2025 setup:

Marketplace footprint cut by 20%, and the company's #1/#2 price position in silver tier going from 50% of markets in 2025 to ~10% in 2026 — explicit prioritization of margin over membership [12].
Marketplace rate increases averaging 30% for 2026 (range 15%–45%) and exit of "difficult geographies" [12].
Medicaid rate cycle re-anchored: 60% of revenue renews January 1, with early reads suggesting full-year rates "modestly in excess of trend" by 50 basis points — small, but the first positive rate/trend gap in six quarters.

Joe Zubretsky's framing in Q1 2026 was telling: he committed to demonstrate at the May 2026 Investor Day "how we will again realize the intrinsic value of the franchise we have built over the past 8 years" [22]. He is implicitly conceding that the intrinsic value the bull case relied on has not been realized yet — that what stretched the 2025 EPS line was a real, durable risk in the Marketplace and Medicaid businesses, and the path back is multi-year.

What the Story Is Now

Credibility Score (1–10)

Current CEO Start Year

2,017

Current Chapter Start Year

2,018

Credibility verdict: 5/10. The Zubretsky team built genuine playbook credibility from 2018 through 2024 — multiple years of "show you the math" guidance walks, four straight years of meeting or beating original EPS guidance, a clean acknowledgement when 2024 missed by 3.6%. That track record is real and would justify a 7 or 8 on its own. But 2025 happened: a 64% miss versus initial guidance, three sequential cuts in a single year (reaffirmed in April, cut in July, cut again in October), and \$1 billion of buybacks executed into the miss. The current 2026 framing is honest and conservative, but the team has not yet shown it can rebuild forward credibility with one quarter of in-line execution. A "5" is the right place to sit until they prove the rate-cycle thesis at the January 2027 reset.

What has been de-risked:

Marketplace exposure is being cut by 20% and dramatically repriced; the segment is being explicitly de-emphasized.
Medicaid is 75% of revenue at a 3.2% pretax margin — bruised but still working.
The Q1 2026 Medicaid trend ran modestly below 5% guidance, the first positive divergence in six quarters.
Embedded-earnings disclosure persists (\$8.65/share carried, including \$2.50 of certain reversals in 2027).

What still looks stretched:

Leverage at 6.1× TTM EBITDA — temporarily but reportedly so, and only because EBITDA itself collapsed.
The 2026 \$5 EPS guidance implies a fundamentally lower run-rate than the 2024 \$20.42.
Medicare bids for 2027 still have to be set against a Duals population whose utilization the team has admitted it under-priced two years running.
The recurring "rate cycle will fix this" framing is now five quarters old and depends on state actuarial behavior the company does not control.

Net: The story today is simpler and more contained than 2024's "compound at 13–15%" arc, but it is not more durable. Credibility is deteriorating quarter-on-quarter through 2025 and starting to stabilize on a much lower base in Q1 2026. Investors should believe the segment-level diagnosis (Marketplace was overweight, rates lagged trend, the bid was wrong), discount the 2026 \$5 floor only modestly, and remain skeptical of any reference to the 2021–2024-era "embedded earnings power" framing until two consecutive Medicaid rate cycles deliver rates clearly in excess of trend. The May 2026 Investor Day is the next material credibility checkpoint.

References

Generated Jun 19, 2026 10:03 UTC